

FREEDOM OF INFORMATION RESPONSE

FOI 3390

Oral mucosilitis

1. How many patients with a diagnosis of cancer also had a diagnosis of oral mucositis (K12.3) in the years: 2014-2015, 2013-2014 and 2012-2013?

Fin Year	Total
2012/13	14
2013/14	22
2014/15	16
Grand Total	52

2. How many patients were admitted to Accident and Emergency (A&E) for Oral Mucositis (K12.3) in the years: 2014-2015, 2013-2014 and 2012-2013?

2012/13	0
2013/14	0
2014/15	0
Grand Total	0

3. For the past year, what was the median length of hospital stay for patients admitted to hospital for oral mucositis, with a previous primary diagnosis of cancer? If possible, please provide the same information for the preceding 2 years.

2012/13	7.0	Days
2013/14	0.5	Days
2014/15	5.0	Days

4. Which products are currently used by the trust in the prevention and treatment of oral mucositis induced by cancer treatment? **Diffiam mouthwash and Gelclair sachets**

5. How much money was spent on each product identified in question 4, in the past year? If possible, please provide the same information for the preceding 2 years. **We are unable to separately identify these costs.**
6. For the last year, how were patients with Oral Mucositis (K12.3) referred to the Trust? If possible, please complete this in the following table format:

DESCRIPTION	Total
A&E DEPT	*
GP REFERRAL	6
INTERNAL CONSULTANT (NOT A&E) EXISTING PATHWAY	5
ISTC CONSULTANT	*
Grand Total	16

* number redacted as under 5.

7. What was the total cost of Oral Mucositis (K12.3) per annum for the trust in the years: 2014-2015, 2013-2014 and 2012-2013? **We are unable to separately identify the costs.**